NASDAQ:IOSPInnospec Stock Price, Forecast & News

Innospec's stock was trading at $72.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IOSP stock has increased by 14.4% and is now trading at $82.87.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innospec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Innospec.

Innospec is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Innospec.

Innospec Inc. (NASDAQ:IOSP) released its quarterly earnings results on Tuesday, August, 4th. The specialty chemicals company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by $0.49. The specialty chemicals company had revenue of $244.90 million for the quarter, compared to analyst estimates of $278.65 million. Innospec had a net margin of 3.96% and a return on equity of 11.10%. The business's revenue was down 32.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.12 EPS.
View Innospec's earnings history.

Innospec announced a semi-annual dividend on Thursday, May 7th. Stockholders of record on Monday, May 18th will be given a dividend of $0.52 per share on Tuesday, May 26th. This represents a yield of 1.5%. The ex-dividend date of this dividend is Friday, May 15th.
View Innospec's dividend history.

1 equities research analysts have issued twelve-month price targets for Innospec's stock. Their forecasts range from $95.00 to $95.00. On average, they expect Innospec's stock price to reach $95.00 in the next year. This suggests a possible upside of 14.6% from the stock's current price.
View analysts' price targets for Innospec.

News coverage about IOSP stock has been trending positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Innospec earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned headlines about the specialty chemicals company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about Innospec.

Innospec saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 540,900 shares, an increase of 26.5% from the June 15th total of 427,600 shares. Based on an average trading volume of 117,500 shares, the short-interest ratio is currently 4.6 days. Approximately 2.2% of the shares of the stock are short sold.
View Innospec's Short Interest.

Some companies that are related to Innospec include Sherwin-Williams (SHW), Ecolab (ECL), International Flavors & Fragrances (IFF), Celanese (CE), RPM International (RPM), Albemarle (ALB), Ashland Global (ASH), NewMarket (NEU), Quaker Chemical (KWR), Balchem (BCPC), W. R. Grace & Co (GRA), Stepan (SCL), HB Fuller (FUL), PolyOne (POL) and Sensient Technologies (SXT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Innospec investors own include Altria Group (MO), Ecolab (ECL), NVIDIA (NVDA), Sherwin-Williams (SHW), Applied Materials (AMAT), Activision Blizzard (ATVI), Broadcom (AVGO), Boeing (BA), Caterpillar (CAT) and Colgate-Palmolive (CL).

Innospec trades on the NASDAQ under the ticker symbol "IOSP."

Innospec's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (12.76%), Wasatch Advisors Inc. (1.26%), Bank of New York Mellon Corp (1.20%), Grantham Mayo Van Otterloo & Co. LLC (1.06%), Principal Financial Group Inc. (0.78%) and Kirr Marbach & Co. LLC IN (0.41%). Company insiders that own Innospec stock include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon.
View institutional ownership trends for Innospec.

IOSP stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., Grantham Mayo Van Otterloo & Co. LLC, Principal Financial Group Inc., First Trust Advisors LP, Prudential Financial Inc., Mackay Shields LLC, and Trexquant Investment LP. Company insiders that have sold Innospec company stock in the last year include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Patrick Williams, and Philip John Boon.
View insider buying and selling activity for Innospec.

IOSP stock was acquired by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, Assenagon Asset Management S.A., Huber Capital Management LLC, UBS Group AG, Marshall Wace LLP, Mutual of America Capital Management LLC, Swiss National Bank, and Barclays PLC.
View insider buying and selling activity for Innospec.

Shares of IOSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IOSP stock can currently be purchased for approximately $82.87.

Innospec has a market capitalization of $2.04 billion and generates $1.51 billion in revenue each year. Innospec employs 2,000 workers across the globe.

The official website for Innospec is www.innospecinc.com.

Innospec's mailing address is 8310 SOUTH VALLEY HIGHWAY SUITE 350, ENGLEWOOD CO, 80112. The specialty chemicals company can be reached via phone at 303-792-5554 or via email at [email protected]